On botulinum neurotoxin variability

mBio

Volumn 6, Issue 1, 2015, Pages

  Montecucco, Cesare ^a   Rasotto, Maria Berica ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN D; BOTULINUM TOXIN E; BOTULINUM TOXIN F; BOTULINUM TOXIN G; UNCLASSIFIED DRUG; NEUROTOXIN;

ARTICLE; BACTERIAL GROWTH; BOTULISM; ECOLOGICAL NICHE; HUMAN; LIFE CYCLE; MORTALITY; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; TOXIN ANALYSIS; TOXIN SYNTHESIS; ANIMAL; CLOSTRIDIUM; METABOLISM; MICROBIOLOGY;

ANIMALIA; CLOSTRIDIUM;

ANIMALS; BOTULISM; CLOSTRIDIUM; HUMANS; NEUROTOXINS;

EID: 84924102121     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02131-14     Document Type: Article

References (54)

1. Kuhn TS. 1962. The structure of scientific revolutions. University of Chicago Press, Chicago, IL.
2. Federal Register. 2012. Possession, use, and transfer of select agents and toxins; biennial review. Final rule. Fed Regist 77: 61083-61115. http://www. gpo. gov/fdsys/pkg/FR-2012-10-05/html/2012-24389. htm.
3. Scott AB, Rosenbaum A, Collins CC. 1973. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12: 924-927.
4. Schantz EJ, Johnson EA. 1992. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56: 80-99.
5. Montecucco C, Molgò J. 2005. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 5: 274-279. http://dx. doi. org/10. 1016/j. coph. 2004. 12. 006.
6. Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J. 2013. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 67: 94-114. http://dx. doi. org/10. 1016/j. toxicon. 2012. 12. 004.
7. Smith LD, Sugiyama H. 1988. Botulism: the organism, its toxins, the disease. Charles C. Thomas Publishers, Springfield, IL.
8. Johnson EA, Montecucco C. 2008. Botulism. Handb. Clin Neurol 91: 333-368. http://dx. doi. org/10. 1016/S0072-9752(07)01511-4.
9. Dover N, Barash JR, Hill KK, Xie G, Arnon SS. 2014. Molecular characterization of a novel botulinum neurotoxin typeHgene. J Infect Dis 209: 192-202. http://dx. doi. org/10. 1093/infdis/jit450.
10. Rossetto O, Pirazzini M, Montecucco C. 2014. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12: 535-549. http://dx. doi. org/10. 1038/nrmicro3295.
11. Gimenez DF, Ciccarelli AS. 1970. Another type of Clostridium botulinum. Zentralbl Bakteriol Orig 215: 221-224.
12. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. 1998. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5: 898-902. http://dx. doi. org/10. 1038/2338.
13. Swaminathan S, Eswaramoorthy S. 2000. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 7: 693-699. http://dx. doi. org/10. 1038/78005.
14. Montal M. 2010. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 79: 591-617. http://dx. doi. org/10. 1146/annurev. biochem. 051908. 125345.
15. Montecucco C, Rossetto O, Schiavo G. 2004. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol 12: 442-446. http://dx. doi. org/10. 1016/j. tim. 2004. 08. 002.
16. Kammerer RA, Benoit RM. 2014. Botulinum neurotoxins: new questions arising from structural biology. Trends Biochem Sci 39: 517-526. http://dx. doi. org/10. 1016/j. tibs. 2014. 08. 009.
17. Fischer A, Montal M. 2007. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem 282: 29604-29611. http://dx. doi. org/10. 1074/jbc. M703619200.
18. Pirazzini M, Bordin F, Rossetto O, Shone CC, Binz T, Montecucco C. 2013. The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals. FEBS Lett 587: 150-155. http://dx. doi. org/10. 1016/j. febslet. 2012. 11. 007.
19. Pirazzini M, Azarnia Tehran D, Zanetti G, Megighian A, Scorzeto M, Fillo S, Shone CC, Binz T, Rossetto O, Lista F, Montecucco C. 2014. Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep 8: 1870-1878. http://dx. doi. org/10. 1016/j. celrep. 2014. 08. 017.
20. Binz T. 2013. Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission. Curr Top Microbiol Immunol 364: 139-157. http://dx. doi. org/10. 1007/978-3-642-33570-9_7.
21. Pantano S, Montecucco C. 2014. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol Life Sci 71: 793-811. http://dx. doi. org/10. 1007/s00018-013-1380-7.
22. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C. 1998. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256: 135-138. http://dx. doi. org/10. 1016/S0304-3940(98)00775-7.
23. Rossetto O, Schiavo G, Montecucco C, Poulain B, Deloye F, Lozzi L, Shone CC. 1994. SNARE motif and neurotoxins. Nature 372: 415-416. http://dx. doi. org/10. 1038/372415a0.
24. Brunger AT, Rummel A. 2009. Receptor and substrate interactions of clostridal neurotoxins. Toxicon 54: 550-560. http://dx. doi. org/10. 1016/j. toxicon. 2008. 12. 027.
25. Hill KK, Smith TJ. 2013. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol 364: 1-20. http://dx. doi. org/10. 1007/978-3-642-33570-9_1.
26. Wang D, Zhang Z, Dong M, Sun S, Chapman ER, Jackson MB. 2011. Syntaxin requirement for Ca2+-triggered exocytosis in neurons and endocrine cells demonstrated with an engineered neurotoxin. Biochemistry 50: 2711-2713. http://dx. doi. org/10. 1021/bi200290p.
27. Pirazzini M, Henke T, Rossetto O, Mahrhold S, Krez N, Rummel A, Montecucco C, Binz T. 2013. Neutralisation of specific surface carboxylates speeds up translocationof botulinum neurotoxin type B enzymatic domain. FEBS Lett 587: 3831-3836. http://dx. doi. org/10. 1016/j. febslet. 2013. 10. 010.
28. Montal M. 2014. Redox regulation of botulinum neurotoxin toxicity: therapeutic implications. Trends Mol Med 20: 602-603. http://dx. doi. org/10. 1016/j. molmed. 2014. 09. 005.
29. Casadevall A, Pirofski LA. 2007. Accidental virulence, cryptic pathogenesis, Martians, lost hosts, and the pathogenicity of environmental microbes. Eukaryot Cell 6: 2169-2174. http://dx. doi. org/10. 1128/EC. 00308-07.
30. Eklund MW, Dowell VR. 1987. Avian botulism. An international perspective. Charles C. Thomas Publishers, Springfield, IL.
31. Horowitz BZ. 2010. Type E botulism. Clin Toxicol (Phila) 48: 880-895. http://dx. doi. org/10. 3109/15563650. 2010. 526943.
32. Darwin C. 1859. On the origin of species by means of natural selection, or the preservation of favoured races in the struggle for life. John Murray, London, United Kingdom.
33. Kimura M. 1991. The neutral theory of molecular evolution: a review of recent evidence. Jpn J Genet 66: 367-386. http://dx. doi. org/10. 1266/jjg. 66. 367.
34. Kalb SR, Baudys J, Webb RP, Wright P, Smith TJ, Smith LA, Fernández R, Raphael BH, Maslanka SE, Pirkle JL, Barr JR. 2012. Discovery of a novel enzymatic cleavage site for botulinum neurotoxin F5. FEBS Lett 586: 109-115. http://dx. doi. org/10. 1016/j. febslet. 2011. 11. 033.
35. Mukai Y, Shimatani Y, Sako W, Asanuma K, Nodera H, Sakamoto T, Izumi Y, Kohda T, Kozaki S, Kaji R. 2014. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals. Toxicon 81: 32-36. http://dx. doi. org/10. 1016/j. toxicon. 2013. 12. 012.
36. Pier CL, Chen C, Tepp WH, Lin G, Janda KD, Barbieri JT, Pellett S, Johnson EA. 2011. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett 585: 199-206. http://dx. doi. org/10. 1016/j. febslet. 2010. 11. 045.
37. Whitemarsh RC, Tepp WH, Bradshaw M, Lin G, Pier CL, Scherf JM, Johnson EA, Pellett S. 2013. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun 81: 3894-3902. http://dx. doi. org/10. 1128/IAI. 00536-13.
38. Whitemarsh RC, Tepp WH, Johnson EA, Pellett S. 2014. Persistence of botulinum neurotoxin A subtypes 1-5 in primary rat spinal cord cells. PLoS One 9: e90252. http://dx. doi. org/10. 1371/journal. pone. 0090252.
39. Gu S, Jin R. 2013. Assembly and function of the botulinum neurotoxin progenitor complex. Curr Top Microbiol Immunol 364: 21-44. http://dx. doi. org/10. 1007/978-3-642-33570-9_2.
40. Fujinaga Y, Sugawara Y, Matsumura T. 2013. Uptake of botulinum neurotoxin in the intestine. Curr Top Microbiol Immunol 364: 45-59. http://dx. doi. org/10. 1007/978-3-642-33570-9_3.
41. Gu S, Rumpel S, Zhou J, Strotmeier J, Bigalke H, Perry K, Shoemaker CB, Rummel A, Jin R. 2012. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335: 977-981. http://dx. doi. org/10. 1126/science. 1214270.
42. Baldari CT, Tonello F, Paccani SR, Montecucco C. 2006. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol 27: 434-440. http://dx. doi. org/10. 1016/j. it. 2006. 07. 002.
43. Cintra-Francischinelli M, Pizzo P, Rodrigues-Simioni L, Ponce-Soto LA, Rossetto O, Lomonte B, Gutiérrez JM, Pozzan T, Montecucco C. 2009. Calcium imaging of muscle cells treated with snake myotoxins reveals toxin synergism and presence of acceptors. Cell Mol Life Sci 66: 1718-1728. http://dx. doi. org/10. 1007/s00018-009-9053-2.
44. Mora-Obando D, Fernández J, Montecucco C, Gutiérrez JM, Lomonte B. 2014. Synergism between basic Asp49 and Lys49 phospholipase A2 myotoxins of viperid snake venom in vitro and in vivo. PLoS One 9: e109846. http://dx. doi. org/10. 1371/journal. pone. 0109846.
45. Ohishi I, Iwasaki M, Sakaguchi G. 1980. Purification and characterization of two components of botulinum C2 toxin. Infect Immun 30: 668-673.
46. Simpson L. 2013. The life history of a botulinum toxin molecule. Toxicon 68: 40-59. http://dx. doi. org/10. 1016/j. toxicon. 2013. 02. 014.
47. Rummel A. 2013. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr Top Microbiol Immunol 364: 61-90. http://dx. doi. org/10. 1007/978-3-642-33570-9_4.
48. Koriazova LK, Montal M. 2003. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10: 13-18. http://dx. doi. org/10. 1038/nsb879.
49. Pirazzini M, Rossetto O, Bolognese P, Shone CC, Montecucco C. 2011. Double anchorage to the membrane and intact inter-chain disulfide bond are required for the low pH induced entry of tetanus and botulinum neurotoxins into neurons. Cell Microbiol 13: 1731-1743. http://dx. doi. org/10. 1111/j. 1462-5822. 2011. 01654. x.
50. Sun S, Suresh S, Liu H, Tepp WH, Johnson EA, Edwardson JM, Chapman ER. 2011. Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly. Cell Host Microbe 10: 237-247. http://dx. doi. org/10. 1016/j. chom. 2011. 06. 012.
51. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C. 1998. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256: 135-138. http://dx. doi. org/10. 1016/S0304-3940(98)00775-7.
52. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C. 2004. Different types of botulinum toxin in humans. Mov Disord 19(Suppl 8): S53-S59. http://dx. doi. org/10. 1002/mds. 20010.
53. Keller JE. 2006. Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 139: 629-637. h t t p://d x. d o i. o r g/1 0. 1 0 1 6/j. neuroscience. 2005. 12. 029.
54. Broide RS, Rubino J, Nicholson GS, Ardila MC, Brown MS, Aoki KR, Francis J. 2013. The rat digit abduction score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis. Toxicon 71: 18-24. http://dx. doi. org/10. 1016/j. toxicon. 2013. 05. 004.